Antigen discovery for development of personalized cancer immunotherapy.
Michal Bassani, University of Lausanne
Cancer immunotherapy has revolutionized the clinical outcome of patients. At the Department of Oncology at the CHUV, several personalized cancer vaccines and adoptive T cells based therapy phase I trials have been launched and a few more are under development. These exploratory therapies are based on the activation of the immune system to recognize and eliminate tumors based on recognition of mutated neoantigens presented specifically on the surface of cancer cells. Mutations are often private to each patient, hence comprehensive target discovery approaches have been put in place, including whole exome sequencing, transcriptomics and mass spectrometry based immunopeptidomics analyses. The computation analyses of such sensitive data must be completed within a define timeframe required for the manufacturing of the treatment products. In my presentation, I will describe our computational and experimental pipeline for antigen discovery that we have developed for these trials.
An introduction to CyTOF technology for high-multiplex cell suspension and imaging applications
Anne-Sophie Thomas-Claudepierre, fluidigm
The next-generation mass cytometer, CyTOF XT, redefines high parameter cytometry with advances in automation, throughput, time to results and total cost of ownership. Built to simplify the design and execution of deep cell profiling studies, CyTOF XT™ standardizes sample analysis with reproducible workflows and automation to accelerate novel therapeutic development and improve human health.
With Imaging Mass Cytometry™ (IMC™), also based on established CyTOF® technology, researchers have access to the world’s first and most proven approach to high-multiplex imaging and single cell protein analysis. With the possibility of analyzing the tissue microenvironment with single cell resolution, researchers can now generate novel research hypotheses with fewer samples in one scan. Enjoy flexible panel design without panel or antibody limitations or concern about antibody order or label assignment. Eliminate autofluorescence, create compact easy to work with data files and avoid timely and costly cyclic tests.